AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12554916 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K prophylaxis in severely ill patients on extended periods of antibiotics and inadequate diet
Number of subjects: 0
Study 12554916 — intervention group
Group type: COMPARATOR
Intervention: Prolonged antibiotic therapy
Number of subjects: 0
Study 10477036 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 and omega-6 EFAs
Number of subjects: 20
Study 10477036 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sunflower oil)
Number of subjects: 20
Study 8753919 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 50
Study 8753919 — intervention group
Group type: COMPARATOR
Intervention: Intradural anesthesia
Number of subjects: 50
Study 1840166 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylonest 3% Octapressin
Number of subjects: 220
Study 1840166 — intervention group
Group type: COMPARATOR
Intervention: Scandicain
Number of subjects: 220
Study 6366137 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 years of chemotherapy
Number of subjects: 316
Study 6366137 — intervention group
Group type: COMPARATOR
Intervention: 5 years of chemotherapy
Number of subjects: 316
Study 31747948 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 weeks trastuzumab
Number of subjects: 1244
Study 31747948 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 year trastuzumab
Number of subjects: 1244
Study 31747948 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic stage
Number of subjects: 1244
Study 31747948 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomic stage
Number of subjects: 1244
Study 29787831 — intervention group
Group type: EXPERIMENTAL
Intervention: Oleoylethanolamide (OEA) 125 mg capsules, two capsules daily for 60 days
Number of subjects: 60
Study 29787831 — intervention group
Group type: COMPARATOR
Intervention: Placebo (starches)
Number of subjects: 60
Study 27236486 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg sublingual testosterone
Number of subjects: 26
Study 27236486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 24905918 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching (SS)
Number of subjects: 11
Study 24905918 — intervention group
Group type: COMPARATOR
Intervention: Control (no static stretching)
Number of subjects: 11
Study 22168946 — intervention group
Group type: EXPERIMENTAL
Intervention: Process-oriented training program for midwives and postnatal nurses (n=206)
Number of subjects: 540
Study 22168946 — intervention group
Group type: COMPARATOR
Intervention: Control group A (CGA) (n=162)
Number of subjects: 540
Study 22168946 — intervention group
Group type: COMPARATOR
Intervention: Control group B (CGB) (n=172)
Number of subjects: 540
Study 19653488 — intervention group
Group type: EXPERIMENTAL
Intervention: Using a cell phone
Number of subjects: 0
Study 19653488 — intervention group
Group type: COMPARATOR
Intervention: Not using a cell phone
Number of subjects: 0
Study 17557985 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) high in catechins (583 mg of catechins per day)
Number of subjects: 240
Study 17557985 — intervention group
Group type: COMPARATOR
Intervention: Control group (96 mg of catechins per day)
Number of subjects: 240
Study 15161992 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately early dexamethasone (MED) group
Number of subjects: 40
Study 15161992 — intervention group
Group type: EXPERIMENTAL
Intervention: Early dexamethasone (ED) group
Number of subjects: 40
Study 15161992 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 12189112 — intervention group
Group type: EXPERIMENTAL
Intervention: bisoprolol (5 mg/d)
Number of subjects: 331
Study 12189112 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril (10 mg/d)
Number of subjects: 331
Study 12189112 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine retard (20 mg/day)
Number of subjects: 331
Study 9815204 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural rotavirus infection (symptomatic infection)
Number of subjects: 1185
Study 9815204 — intervention group
Group type: COMPARATOR
Intervention: Initial symptomatic infection (placebo group)
Number of subjects: 1185
Study 9815204 — intervention group
Group type: COMPARATOR
Intervention: Initial serotype G3 episode (placebo group)
Number of subjects: 1185
Study 7661122 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg beta-carotene daily for 3 weeks
Number of subjects: 0
Study 7661122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7661122 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg beta-carotene oral dose
Number of subjects: 0
Study 7661122 — intervention group
Group type: COMPARATOR
Intervention: No beta-carotene
Number of subjects: 0
Study 2649822 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser vaporization
Number of subjects: 100
Study 2649822 — intervention group
Group type: COMPARATOR
Intervention: Laser excision conization
Number of subjects: 100
Study 1096541 — intervention group
Group type: EXPERIMENTAL
Intervention: Penfluridol (peroral)
Number of subjects: 56
Study 1096541 — intervention group
Group type: COMPARATOR
Intervention: Flupenthixol decanoate (parenteral)
Number of subjects: 56
Study 1096541 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs (penfluridol and flupenthixol decanoate)
Number of subjects: 56
Study 31068212 — intervention group
Group type: EXPERIMENTAL
Intervention: High positive end-expiratory pressure (PEEP) during one-lung ventilation
Number of subjects: 0
Study 31068212 — intervention group
Group type: COMPARATOR
Intervention: Low positive end-expiratory pressure (PEEP) during one-lung ventilation
Number of subjects: 0
Study 28488937 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional balance training
Number of subjects: 43
Study 28488937 — intervention group
Group type: EXPERIMENTAL
Intervention: Slackline training
Number of subjects: 43
Study 28488937 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 43
Study 25950433 — intervention group
Group type: EXPERIMENTAL
Intervention: 2011/12 seasonal influenza DNA vaccine prime
Number of subjects: 131
Study 25950433 — intervention group
Group type: COMPARATOR
Intervention: Phosphate buffered saline (PBS)
Number of subjects: 131
Study 23384589 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing contact through follow-up telephone calls
Number of subjects: 0
Study 23384589 — intervention group
Group type: EXPERIMENTAL
Intervention: Providing collaterals
Number of subjects: 0
Study 23384589 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving more than four telephone calls
Number of subjects: 0
Study 21563210 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticholinergic medication with or without behavioral therapy
Number of subjects: 307
Study 18698222 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril 40 mg
Number of subjects: 133
Study 18698222 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 320 mg
Number of subjects: 133
Study 18698222 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan/Lisinopril 320/20 mg
Number of subjects: 133
Study 17138309 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-demonstration contact with test stimuli
Number of subjects: 50
Study 17138309 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-demonstration contact with test stimuli
Number of subjects: 50
Study 17138309 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferred imitation paradigm
Number of subjects: 50
Study 17138309 — intervention group
Group type: EXPERIMENTAL
Intervention: Elicited imitation paradigm
Number of subjects: 50
Study 14743888 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan
Number of subjects: 0
Study 14743888 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin in combination with 5-fluoro-uracil (5-FU) and leucovorin
Number of subjects: 0
Study 14743888 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prodrugs of 5-FU (capecitabine and uracil)
Number of subjects: 0
Study 14743888 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibodies and small molecules targeting EGFR and VEGF
Number of subjects: 0
Study 10899744 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 x 300 mg extractum Valerianae radix siccum dragées LI 156
Number of subjects: 75
Study 10899744 — intervention group
Group type: COMPARATOR
Intervention: 2 x 5 mg oxazepam dragées
Number of subjects: 75
Study 8970248 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2% solution
Number of subjects: 206
Study 8970248 — intervention group
Group type: COMPARATOR
Intervention: Betaxolol 0.25% suspension
Number of subjects: 206
Study 1471517 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam + Buprenorphine
Number of subjects: 81
Study 1471517 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine alone
Number of subjects: 81
Study 6344893 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoprofen 100 mg
Number of subjects: 100
Study 6344893 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoprofen 200 mg
Number of subjects: 100
Study 6344893 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoprofen 400 mg (i.v. bolus + 2-h infusion)
Number of subjects: 100
Study 6344893 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoprofen 400 mg (i.v. bolus alone)
Number of subjects: 100
Study 6344893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 31160812 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop digital meditation (MediTrain) delivered on mobile devices for 6 weeks
Number of subjects: 0
Study 28898688 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision support mobile digital platform
Number of subjects: 34
Study 28898688 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study 26420269 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation at an intensity of 2 mA for 20 minutes daily for 10 consecutive days (dorsolateral prefrontal cortex group)
Number of subjects: 60
Study 26420269 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation at an intensity of 2 mA for 20 minutes daily for 10 consecutive days (cingulo-opercular network group)
Number of subjects: 60
Study 26420269 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation at an intensity of 2 mA for 20 minutes daily for 10 consecutive days (motor primary cortex group)
Number of subjects: 60
Study 26420269 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 60
Study 24144788 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 5 mg twice daily with concomitant aspirin
Number of subjects: 18201
Study 24144788 — intervention group
Group type: COMPARATOR
Intervention: Warfarin with concomitant aspirin
Number of subjects: 18201
Study 24144788 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 5 mg twice daily without concomitant aspirin
Number of subjects: 18201
Study 24144788 — intervention group
Group type: COMPARATOR
Intervention: Warfarin without concomitant aspirin
Number of subjects: 18201
Study 23226553 — intervention group
Group type: EXPERIMENTAL
Intervention: FIFA 11+
Number of subjects: 36
Study 23226553 — intervention group
Group type: EXPERIMENTAL
Intervention: HarmoKnee
Number of subjects: 36
Study 23226553 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 36
Study 19157997 — intervention group
Group type: EXPERIMENTAL
Intervention: RU38486 (mifepristone)
Number of subjects: 0
Study 19157997 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal standard (alfaxolone)
Number of subjects: 0
Study 17466461 — intervention group
Group type: EXPERIMENTAL
Intervention: BRT protocol
Number of subjects: 0
Study 17466461 — intervention group
Group type: COMPARATOR
Intervention: Routine burn rehabilitation treatment
Number of subjects: 0
Study 15894098 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted surgery
Number of subjects: 794
Study 15894098 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 794
Study 9711448 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 360 mg/day for 12 weeks
Number of subjects: 0
Study 9711448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9711448 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 0
Study 7883739 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex
Number of subjects: 0
Study 7883739 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 0
Study 7883739 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 0
Study 2677374 — intervention group
Group type: EXPERIMENTAL
Intervention: H142 at 1.0 mg/kg/h
Number of subjects: 1
Study 2677374 — intervention group
Group type: EXPERIMENTAL
Intervention: H142 at 2.5 mg/kg/h
Number of subjects: 1
Study 2677374 — intervention group
Group type: EXPERIMENTAL
Intervention: H142 at 5.0 mg/kg/h
Number of subjects: 1
Study 2677374 — intervention group
Group type: EXPERIMENTAL
Intervention: H142 (all doses)
Number of subjects: 1
Study 2677374 — intervention group
Group type: EXPERIMENTAL
Intervention: H142 (after stopping)
Number of subjects: 1
Study 356925 — intervention group
Group type: EXPERIMENTAL
Intervention: multivitamin‐electrolyte‐preparation
Number of subjects: 40
Study 356925 — intervention group
Group type: EXPERIMENTAL
Intervention: B1, B2 and B6 deficiencies
Number of subjects: 40
Study 30076614 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin (2-12 mg/day)
Number of subjects: 120
Study 31007053 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based occupational therapy (Group BOT, n=43)
Number of subjects: 181
Study 31007053 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based physiotherapy (Group BPT, n=42)
Number of subjects: 181
Study 31007053 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation programme only (Group A, n=96)
Number of subjects: 181
Study 28027937 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical glyceryl trinitrate (GTN)
Number of subjects: 16
Study 28027937 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 16
Study 25998582 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 400 μg
Number of subjects: 1136
Study 25998582 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 30 mg
Number of subjects: 1136
Study 25998582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1136
Study 25998582 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin vs Nifedipine
Number of subjects: 1136
Study 23633761 — intervention group
Group type: EXPERIMENTAL
Intervention: MEMS-accelerometry
Number of subjects: 15
Study 21309005 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin (10 mg/day)
Number of subjects: 72
Study 21309005 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 72
Study 19950087 — intervention group
Group type: EXPERIMENTAL
Intervention: PTRA + IVBT
Number of subjects: 71
Study 19950087 — intervention group
Group type: COMPARATOR
Intervention: PTRA
Number of subjects: 71
Study 17667835 — intervention group
Group type: EXPERIMENTAL
Intervention: Versajet system
Number of subjects: 87
Study 17667835 — intervention group
Group type: COMPARATOR
Intervention: Hand-held dermatome escharectomy
Number of subjects: 87
Study 15618271 — intervention group
Group type: EXPERIMENTAL
Intervention: H1 receptor antagonist (540 mg oral fexofenadine hydrochloride; Allegra)
Number of subjects: 14
Study 15618271 — intervention group
Group type: COMPARATOR
Intervention: Control (no H1 receptor antagonist)
Number of subjects: 14
Study 12518534 — intervention group
Group type: EXPERIMENTAL
Intervention: Eradication of Helicobacter pylori infection using triple therapy (pantoprazole + amoxicillin + clarithromycin)
Number of subjects: 97
Study 12518534 — intervention group
Group type: COMPARATOR
Intervention: Control group with Helicobacter positive infection
Number of subjects: 97
Study 9578506 — intervention group
Group type: EXPERIMENTAL
Intervention: GH therapy (18 units/m2 per week divided into daily s.c. doses) for 1 year
Number of subjects: 41
Study 9578506 — intervention group
Group type: COMPARATOR
Intervention: GH response to provocation by clonidine and glucagon
Number of subjects: 41
Study 9578506 — intervention group
Group type: COMPARATOR
Intervention: IGF‐I generation test after GH injection
Number of subjects: 41
Study 9578506 — intervention group
Group type: COMPARATOR
Intervention: Correlation of serum ferritin concentration with GH peak response to provocation
Number of subjects: 41
Study 7645033 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF 2 g treatment group (1.0 g b.i.d.)
Number of subjects: 499
Study 7645033 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF 3 g treatment group (1.5 g b.i.d.)
Number of subjects: 499
Study 7645033 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine group (1-2 mg/kg/day)
Number of subjects: 499
Study 7645033 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF 2 g treatment group
Number of subjects: 499
Study 7645033 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF 3 g treatment group
Number of subjects: 499
Study 7645033 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine group
Number of subjects: 499
Study 7645033 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 499
Study 2694923 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 capsules (1.26 g omega-3 fatty acids)
Number of subjects: 30
Study 2694923 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 capsules (2.52 g omega-3 fatty acids)
Number of subjects: 30
Study 2694923 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose fish oil (4 capsules)
Number of subjects: 30
Study 2694923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 582710 — intervention group
Group type: EXPERIMENTAL
Intervention: Indometacin (150 mg daily)
Number of subjects: 40
Study 582710 — intervention group
Group type: COMPARATOR
Intervention: Glucametacin (420 mg daily)
Number of subjects: 40
Study 31564841 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week progressive vigorous interval training program (3 times per week)
Number of subjects: 77
Study 31564841 — intervention group
Group type: COMPARATOR
Intervention: Control group (maintained daily living and routines)
Number of subjects: 77
Study 29523175 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 0
Study 29523175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27040455 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D stored RBCs
Number of subjects: 0
Study 27040455 — intervention group
Group type: COMPARATOR
Intervention: 35D stored RBCs
Number of subjects: 0
Study 27040455 — intervention group
Group type: EXPERIMENTAL
Intervention: PS exposure, lactadherin binding, CD47 expression
Number of subjects: 0
Study 25295437 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 245
Study 25295437 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 245
Study 22268518 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 2 mg
Number of subjects: 87
Study 22268518 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 10 mg
Number of subjects: 87
Study 20072786 — intervention group
Group type: EXPERIMENTAL
Intervention: Photorefractive keratectomy (PRK)
Number of subjects: 119
Study 20072786 — intervention group
Group type: COMPARATOR
Intervention: Laser in situ keratomileusis (LASIK)
Number of subjects: 119
Study 18095810 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuPH20 150 U
Number of subjects: 54
Study 18095810 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuPH20 750 U
Number of subjects: 54
Study 18095810 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuPH20 1500 U
Number of subjects: 54
Study 18095810 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo (150 U)
Number of subjects: 54
Study 18095810 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo (750 U)
Number of subjects: 54
Study 18095810 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo (1500 U)
Number of subjects: 54
Study 15692543 — intervention group
Group type: COMPARATOR
Intervention: Ketoprofen (100 mg)
Number of subjects: 120
Study 15692543 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib (200 mg)
Number of subjects: 120
Study 15692543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 11815543 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusions guided by peripheral FOE measurements (NIRS group)
Number of subjects: 74
Study 11815543 — intervention group
Group type: COMPARATOR
Intervention: Transfusions guided by conventional protocol based on Hb (conventional group)
Number of subjects: 74
Study 11815543 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 74
Study 10401920 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 283
Study 10401920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 283
Study 7588829 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin 4 mg/kg q 24h i.v.
Number of subjects: 174
Study 7588829 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin 1.33 mg/kg q 8h i.v. (thrice-daily)
Number of subjects: 174
Study 7588829 — intervention group
Group type: EXPERIMENTAL
Intervention: Netilmicin 5.5 mg/kg q 24h i.v.
Number of subjects: 174
Study 2378175 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pulse methylprednisolone 1000 mg
Number of subjects: 0
Study 2378175 — intervention group
Group type: COMPARATOR
Intervention: Intravenous pulse methylprednisolone 250 mg
Number of subjects: 0
Study 2378175 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dosages of intravenous methylprednisolone
Number of subjects: 0
Study 35399 — intervention group
Group type: EXPERIMENTAL
Intervention: Ypsilon-Y IUD
Number of subjects: 300
Study 35399 — intervention group
Group type: COMPARATOR
Intervention: Lippes Loop D
Number of subjects: 300
Study 31801940 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab (300 mg first week, followed by 1000 mg every 8 weeks for up to 2 years)
Number of subjects: 480
Study 31801940 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 480
Study 31801940 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Number of subjects: 480
Study 27879176 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus-of-attention behavioral experiment (FABE)
Number of subjects: 45